For the Inventor, By the Inventor

Enter assignee name

Frankfurt-am-Main, Germany

Aeterna Zentaris Gmbh

USPTO Granted Patents = 36

CIPO Patents = 2

EPO Patents = 2

Trademarks = 3

Forward Citations = 103

Loading Chart...

Loading Chart...

59 inventors (with patents filed for the assignee):

Eckhard Guenther (12 out of 16 patents)

Irene Seipelt (11 out of 13 patents)

Eckhard Günther (11 out of 23 patents)

4. Tilmann Schuster (10 out of 14 patents)

5. Matthias Gerlach (10 out of 31 patents)

6. Emmanuel Polymeropoulos (9 out of 24 patents)

7. Eckhard Claus (8 out of 11 patents)

8. Michael Teifel (7 out of 12 patents)

9. Jürgen Engel (6 out of 10 patents)

10. Klaus Paulini (6 out of 8 patents)

11. Herbert Sindermann (5 out of 5 patents)

12. Gilbert Mueller (4 out of 4 patents)

13. Ulf R Rapp (4 out of 6 patents)

14. Peter Schmidt (4 out of 7 patents)

15. Silke Baasner (3 out of 11 patents)

36 patents: Sort by Forward Citations

1. 10288629 - Method of assessing growth hormone deficiency in humans by a macimorelin containing composition (2019-05-14),

2. 8921318 - Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits (2014-12-30),

3. 8912189 - Pyridopyrazine derivatives and their use (2014-12-16),

4. 8791118 - Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors (2014-07-29),

5. 8679473 - Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof (2014-03-25),

6. 8658615 - Prohibitin as target for cancer therapy (2014-02-25),

7. 8604196 - Modulating signal transduction pathways with 1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2.3-B]pyrazine-6-yl]thiourea (2013-12-10),

8. 8551977 - Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals (2013-10-08),

9. 8546435 - Triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors (2013-10-01),

10. 8541462 - Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors (2013-09-24),

11. 8536332 - Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines (2013-09-17),

12. 8507710 - Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals (2013-08-13),

13. 8507486 - Pyridopyrazine derivatives, process of manufacturing and uses thereof (2013-08-13),

14. 8470776 - Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof (2013-06-25),

15. 8461178 - Naphthyridine derivatives and the use thereof as kinase inhibitors (2013-06-11),

Aeterna Zentaris GmbH is a biopharmaceutical company focused on developing and commercializing therapies for oncology and endocrine disorders. With a strong pipeline of innovative drug candidates, Aeterna Zentaris strives to improve the lives of patients worldwide. For more information, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

36 Patents

#27 in Frankfurt-am-Main

#1,417 in Germany

#18,176 in the World

Frankfurt-am-Main, Germany

Aeterna Zentaris Gmbh

Forward Citations = 103

59 inventors:

Eckhard Guenther (12 out of 16 patents)

Irene Seipelt (11 out of 13 patents)

Eckhard Günther (11 out of 23 patents)

4. Tilmann Schuster (10 out of 14 patents)

5. Matthias Gerlach (10 out of 31 patents)

Please report any incorrect information to support@idiyas.com

Loading…